Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA

Clinical trial NCT07343661 · ENROLLING_BY_INVITATION

Trial details

NCT number: NCT07343661
Sponsor: Azienda Ospedaliero Universitaria di Cagliari
Status: ENROLLING_BY_INVITATION
Phase: Phase 4
Study type: INTERVENTIONAL

EGPA - Eosinophilic Granulomatosis With Polyangiitis Severe Asthma Eosinophilic Asthma

Start date: 2025-10-17
Primary completion: 2026-10-17
Enrollment: 90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.